These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28776405)

  • 1. Power estimation in biomarker studies where events are already observed.
    Polley MC
    Clin Trials; 2017 Dec; 14(6):621-628. PubMed ID: 28776405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for power calculations in predictive biomarker studies in survival data.
    Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
    Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of archived specimens in evaluation of prognostic and predictive biomarkers.
    Simon RM; Paik S; Hayes DF
    J Natl Cancer Inst; 2009 Nov; 101(21):1446-52. PubMed ID: 19815849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the quality of biomarker discovery research: the right samples and enough of them.
    Pepe MS; Li CI; Feng Z
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):944-50. PubMed ID: 25837819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker research with prospective study designs for the early detection of cancer.
    Pesch B; Brüning T; Johnen G; Casjens S; Bonberg N; Taeger D; Müller A; Weber DG; Behrens T
    Biochim Biophys Acta; 2014 May; 1844(5):874-83. PubMed ID: 24361552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size methods for evaluation of predictive biomarkers.
    Dobbin KK; McShane LM
    Stat Med; 2022 Jul; 41(16):3199-3210. PubMed ID: 35491401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarker validation in practice: lessons from real trials.
    Mandrekar SJ; Sargent DJ
    Clin Trials; 2010 Oct; 7(5):567-73. PubMed ID: 20392785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simulation study on estimating biomarker-treatment interaction effects in randomized trials with prognostic variables.
    Haller B; Ulm K
    Trials; 2018 Feb; 19(1):128. PubMed ID: 29463271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating markers for the early detection of cancer: overview of study designs and methods.
    Baker SG; Kramer BS; McIntosh M; Patterson BH; Shyr Y; Skates S
    Clin Trials; 2006; 3(1):43-56. PubMed ID: 16539089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints.
    He P
    Contemp Clin Trials; 2014 Jul; 38(2):333-7. PubMed ID: 24948401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futility for subgroup analyses in the adaptive signature design.
    Callegaro A
    Stat Methods Med Res; 2019 Mar; 28(3):953-961. PubMed ID: 29179654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size and threshold estimation for clinical trials with predictive biomarkers.
    Mackey HM; Bengtsson T
    Contemp Clin Trials; 2013 Nov; 36(2):664-72. PubMed ID: 24064355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Very) Early technology assessment and translation of predictive biomarkers in breast cancer.
    Miquel-Cases A; Schouten PC; Steuten LM; Retèl VP; Linn SC; van Harten WH
    Cancer Treat Rev; 2017 Jan; 52():117-127. PubMed ID: 27992844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies.
    Zhang W; Zhang Z; Krushkal J; Liu A
    BMC Med Res Methodol; 2021 Mar; 21(1):55. PubMed ID: 33740890
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.